Nonprofit revives gene therapy programme abandoned when UK startup Bloomsbury closed
A nonprofit organisation has taken on the lead gene therapy programme of Bloomsbury Genetic Therapies after the UK startup shut down following dosing of just one patient.
A nonprofit organisation has stepped in to continue the lead gene therapy programme developed by Bloomsbury Genetic Therapies, a UK-based startup that closed in 2025 after treating only a single patient. The revival, reported by Stat News on 27 October 2026, illustrates a growing pattern in rare-disease gene therapy: when commercial viability fails, academic institutions, patient foundations, and nonprofits increasingly absorb programmes that would otherwise be abandoned.
Bloomsbury's closure had left the patient community served by the programme without a clear path forward. The nonprofit acquisition preserves the clinical and manufacturing knowledge built up during the programme's development, avoiding the loss of years of work.
The case is relevant to researchers and genetic counsellors as an example of non-commercial gene therapy stewardship. It also connects thematically to broader sector questions about the sustainability of gene therapy business models for ultra-rare diseases — a topic also illustrated by the Pennsylvania Dutch community's independent gene therapy initiative reported by Genetic Current on 27 October 2026.
Specific details about the disease indication, the nonprofit's identity, and the timeline for continuation were not available in full from the paywalled Stat News report.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-27STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down